1
Participants
Start Date
December 8, 2021
Primary Completion Date
August 3, 2022
Study Completion Date
August 3, 2022
human SARS-CoV 2 specific T lymphocytes
"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."
Department I for Internal Medicine University Hospital of Cologne, Cologne
Collaborators (1)
ZKS Köln
OTHER
Hannover Medical School
OTHER
Miltenyi Biomedicine GmbH
INDUSTRY
Universitätsklinikum Köln
OTHER